{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T22:56:58Z","timestamp":1792796218255,"version":"4.5.0"},"reference-count":20,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2023,3,4]],"date-time":"2023-03-04T00:00:00Z","timestamp":1677888000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2023,3,4]],"date-time":"2023-03-04T00:00:00Z","timestamp":1677888000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100005713","name":"Technische Universit\u00e4t M\u00fcnchen","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100005713","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Eur J Nucl Med Mol Imaging"],"published-print":{"date-parts":[[2023,5]]},"DOI":"10.1007\/s00259-023-06177-5","type":"journal-article","created":{"date-parts":[[2023,3,4]],"date-time":"2023-03-04T04:24:29Z","timestamp":1677903869000},"page":"1553-1555","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":52,"title":["FDA approval of lecanemab: the real start of widespread amyloid PET use? \u2014 the EANM Neuroimaging Committee perspective"],"prefix":"10.1007","volume":"50","author":[{"given":"Antoine","family":"Verger","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Igor","family":"Yakushev","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nathalie L.","family":"Albert","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bart","family":"van Berckel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matthias","family":"Brendel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Diego","family":"Cecchin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pablo Aguiar","family":"Fernandez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesco","family":"Fraioli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eric","family":"Guedj","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Silvia","family":"Morbelli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nelleke","family":"Tolboom","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tatjana","family":"Traub-Weidinger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Donatienne","family":"Van Weehaeghe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Henryk","family":"Barthel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,3,4]]},"reference":[{"key":"6177_CR1","doi-asserted-by":"publisher","first-page":"80","DOI":"10.1186\/s13195-021-00813-8","volume":"13","author":"CJ Swanson","year":"2021","unstructured":"Swanson CJ, Zhang Y, Dhadda S, Wang J, Kaplow J, Lai RYK, et al. A randomized, double-blind, phase 2b proof-of-concept clinical trial in early Alzheimer\u2019s disease with lecanemab, an anti-A\u03b2 protofibril antibody. Alzheimers Res Ther. 2021;13:80.","journal-title":"Alzheimers Res Ther"},{"key":"6177_CR2","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1056\/NEJMoa2212948","volume":"388","author":"CH van Dyck","year":"2023","unstructured":"van Dyck CH, Swanson CJ, Aisen P, Bateman RJ, Chen C, Gee M, et al. Lecanemab in early Alzheimer\u2019s disease. N Engl J Med. 2023;388:9\u201321.","journal-title":"N Engl J Med"},{"key":"6177_CR3","doi-asserted-by":"publisher","first-page":"1307","DOI":"10.1001\/jamaneurol.2021.3126","volume":"78","author":"V Planche","year":"2021","unstructured":"Planche V, Villain N. US Food and Drug Administration approval of aducanumab\u2014is amyloid load a valid surrogate end point for Alzheimer disease clinical trials? JAMA Neurol. 2021;78:1307.","journal-title":"JAMA Neurol"},{"key":"6177_CR4","doi-asserted-by":"publisher","first-page":"182","DOI":"10.1186\/s13195-022-01129-x","volume":"14","author":"S Dhadda","year":"2022","unstructured":"Dhadda S, Kanekiyo M, Li D, Swanson CJ, Irizarry M, Berry S, et al. Consistency of efficacy results across various clinical measures and statistical methods in the lecanemab phase 2 trial of early Alzheimer\u2019s disease. Alzheimers Res Ther. 2022;14:182.","journal-title":"Alzheimers Res Ther"},{"key":"6177_CR5","doi-asserted-by":"publisher","unstructured":"S\u00f6derberg L, Johannesson M, Nygren P, Laudon H, Eriksson F, Osswald G, et al. Lecanemab, aducanumab, and gantenerumab \u2014 binding profiles to different forms of amyloid-beta might explain efficacy and side effects in clinical trials for Alzheimer\u2019s disease. Neurotherapeutics 2022. https:\/\/doi.org\/10.1007\/s13311-022-01308-6","DOI":"10.1007\/s13311-022-01308-6"},{"key":"6177_CR6","doi-asserted-by":"publisher","first-page":"322","DOI":"10.1056\/NEJMoa1304839","volume":"370","author":"S Salloway","year":"2014","unstructured":"Salloway S, Sperling R, Fox NC, Blennow K, Klunk W, Raskind M, et al. Two phase 3 trials of bapineuzumab in mild-to-moderate Alzheimer\u2019s disease. N Engl J Med. 2014;370:322\u201333.","journal-title":"N Engl J Med"},{"key":"6177_CR7","doi-asserted-by":"publisher","first-page":"18","DOI":"10.1186\/s13195-016-0189-7","volume":"8","author":"R Vandenberghe","year":"2016","unstructured":"Vandenberghe R, Rinne JO, Boada M, Katayama S, Scheltens P, Vellas B, et al. Bapineuzumab for mild to moderate Alzheimer\u2019s disease in two global, randomized, phase 3 trials. Alzheimers Res Ther. 2016;8:18.","journal-title":"Alzheimers Res Ther"},{"key":"6177_CR8","doi-asserted-by":"publisher","first-page":"321","DOI":"10.1056\/NEJMoa1705971","volume":"378","author":"LS Honig","year":"2018","unstructured":"Honig LS, Vellas B, Woodward M, Boada M, Bullock R, Borrie M, et al. Trial of solanezumab for mild dementia due to Alzheimer\u2019s disease. N Engl J Med. 2018;378:321\u201330.","journal-title":"N Engl J Med"},{"key":"6177_CR9","doi-asserted-by":"publisher","first-page":"95","DOI":"10.1186\/s13195-017-0318-y","volume":"9","author":"S Ostrowitzki","year":"2017","unstructured":"Ostrowitzki S, Lasser RA, Dorflinger E, Scheltens P, Barkhof F, for the SCarletRoAD Investigators, et al. A phase III randomized trial of gantenerumab in prodromal Alzheimer\u2019s disease. Alzheimers Res Ther. 2017;9:95.","journal-title":"Alzheimers Res Ther"},{"key":"6177_CR10","doi-asserted-by":"publisher","first-page":"1","DOI":"10.7573\/dic.2021-7-3","volume":"10","author":"RR Tampi","year":"2021","unstructured":"Tampi RR, Forester BP, Agronin M. Aducanumab: evidence from clinical trial data and controversies. Drugs Context. 2021;10:1\u20139.","journal-title":"Drugs Context"},{"key":"6177_CR11","doi-asserted-by":"publisher","first-page":"1015","DOI":"10.1001\/jamaneurol.2022.2793","volume":"79","author":"S Shcherbinin","year":"2022","unstructured":"Shcherbinin S, Evans CD, Lu M, Andersen SW, Pontecorvo MJ, Willis BA, et al. Association of amyloid reduction after donanemab treatment with tau pathology and clinical outcomes: the TRAILBLAZER-ALZ randomized clinical trial. JAMA Neurol. 2022;79:1015.","journal-title":"JAMA Neurol"},{"key":"6177_CR12","doi-asserted-by":"publisher","first-page":"101339","DOI":"10.1016\/j.arr.2021.101339","volume":"68","author":"KI Avgerinos","year":"2021","unstructured":"Avgerinos KI, Ferrucci L, Kapogiannis D. Effects of monoclonal antibodies against amyloid-\u03b2 on clinical and biomarker outcomes and adverse event risks: a systematic review and meta-analysis of phase III RCTs in Alzheimer\u2019s disease. Ageing Res Rev. 2021;68:101339.","journal-title":"Ageing Res Rev"},{"key":"6177_CR13","doi-asserted-by":"publisher","first-page":"3033","DOI":"10.1007\/s00259-021-05485-y","volume":"48","author":"V Garibotto","year":"2021","unstructured":"Garibotto V, Albert NL, Barthel H, van Berckel B, Boellaard R, Brendel M, et al. The approval of a disease-modifying treatment for Alzheimer\u2019s disease: impact and consequences for the nuclear medicine community. Eur J Nucl Med Mol Imaging. 2021;48:3033\u20136.","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"6177_CR14","doi-asserted-by":"publisher","first-page":"951","DOI":"10.1016\/S1474-4422(20)30314-8","volume":"19","author":"G Ch\u00e9telat","year":"2020","unstructured":"Ch\u00e9telat G, Arbizu J, Barthel H, Garibotto V, Law I, Morbelli S, et al. Amyloid-PET and 18F-FDG-PET in the diagnostic investigation of Alzheimer\u2019s disease and other dementias. Lancet Neurol. 2020;19:951\u201362.","journal-title":"Lancet Neurol"},{"key":"6177_CR15","doi-asserted-by":"publisher","first-page":"4097","DOI":"10.1007\/s00259-022-05846-1","volume":"49","author":"E Peira","year":"2022","unstructured":"Peira E, Poggiali D, Pardini M, Barthel H, Sabri O, Morbelli S, et al. A comparison of advanced semi-quantitative amyloid PET analysis methods. Eur J Nucl Med Mol Imaging. 2022;49:4097\u2013108.","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"6177_CR16","doi-asserted-by":"publisher","first-page":"117","DOI":"10.2967\/jnumed.120.261858","volume":"63","author":"G Biechele","year":"2022","unstructured":"Biechele G, Monasor LS, Wind K, Blume T, Parhizkar S, Arzberger T, et al. Glitter in the darkness? Nonfibrillar \u03b2-amyloid plaque components significantly impact the \u03b2-amyloid PET signal in mouse models of Alzheimer disease. J Nucl Med. 2022;63:117\u201324.","journal-title":"J Nucl Med"},{"key":"6177_CR17","doi-asserted-by":"publisher","first-page":"293","DOI":"10.1016\/j.jalz.2017.09.009","volume":"14","author":"M Ceccaldi","year":"2018","unstructured":"Ceccaldi M, Jonveaux T, Verger A, Krolak-Salmon P, Houzard C, Godefroy O, et al. Added value of 18F-florbetaben amyloid PET in the diagnostic workup of most complex patients with dementia in France: a naturalistic study. Alzheimers Dement J Alzheimers Assoc. 2018;14:293\u2013305.","journal-title":"Alzheimers Dement J Alzheimers Assoc"},{"key":"6177_CR18","doi-asserted-by":"publisher","first-page":"1286","DOI":"10.1001\/jama.2019.2000","volume":"321","author":"GD Rabinovici","year":"2019","unstructured":"Rabinovici GD, Gatsonis C, Apgar C, Chaudhary K, Gareen I, Hanna L, et al. Association of amyloid positron emission tomography with subsequent change in clinical management among Medicare beneficiaries with mild cognitive impairment or dementia. JAMA. 2019;321:1286\u201394.","journal-title":"JAMA"},{"key":"6177_CR19","doi-asserted-by":"publisher","first-page":"388","DOI":"10.1016\/j.jalz.2018.09.003","volume":"15","author":"GB Frisoni","year":"2019","unstructured":"Frisoni GB, Barkhof F, Altomare D, Berkhof J, Boccardi M, Canzoneri E, et al. AMYPAD diagnostic and patient management study: rationale and design. Alzheimers Dement. 2019;15:388\u201399.","journal-title":"Alzheimers Dement"},{"key":"6177_CR20","doi-asserted-by":"publisher","unstructured":"van Maurik IS, Broulikova HM, Mank A, Bakker ED, de Wilde A, Bouwman FH, et al. (2022) A more precise diagnosis by means of amyloid PET contributes to delayed institutionalization, lower mortality, and reduced care costs in a tertiary memory clinic setting. Alzheimers Dement. 2022;alz.12846.\u00a0https:\/\/doi.org\/10.1002\/alz.12846.","DOI":"10.1002\/alz.12846"}],"container-title":["European Journal of Nuclear Medicine and Molecular Imaging"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00259-023-06177-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00259-023-06177-5\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00259-023-06177-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,4,20]],"date-time":"2023-04-20T14:36:28Z","timestamp":1682001388000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00259-023-06177-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,3,4]]},"references-count":20,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2023,5]]}},"alternative-id":["6177"],"URL":"https:\/\/doi.org\/10.1007\/s00259-023-06177-5","relation":{},"ISSN":["1619-7070","1619-7089"],"issn-type":[{"value":"1619-7070","type":"print"},{"value":"1619-7089","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,3,4]]},"assertion":[{"value":"4 March 2023","order":1,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"\u00a0AV has received speaker honoraria from GE Healthcare, Curium and Philips.\u00a0IY has received consultant and lecture fees from ABX-CRO, Blue Earth Diagnostics, and Piramal.\u00a0HB received reader honoraria from Life Molecular Imaging and speaker honoraria from Novartis\/AAA.\u00a0DC (as PI) received a research grant from Life Molecular Imaging and participated in a research grant offered by Ge Healthcare related to Amyloid PET imaging.\u00a0MB received speaker honoraria from Roche, GE healthcare and Life Molecular Imaging and is an advisor to Life Molecular Imaging.\u00a0The other authors declares that they have no conflict of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}